GOTHENBURG, SE / ACCESSWIRE / November 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November 29, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will present at the ABGSC Investor Days on Wednesday, December 4, 2024, in Stockholm, Sweden.
Kristina Torfgård, CEO, will participate in the event. The company will be presented at 10:00-10:30 CET on December 4, 2024. This event is held at Hotel At Six, Brunkebergstorg 6, Stockholm, and is live-streamed.
More information can be found on the event webpage at: https://cr.abgsc.com/artiklar/2024/10/abgsc-investor-days-4-5-december/
About IRLAB
IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on balance and fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se .
Attachments
IRLAB to present at ABGSC Investor Days on December 4, 2024
SOURCE: IRLAB Therapeutics
View the original press release on accesswire.com
